ArticleAntimicrobial agents and chemotherapy2007
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Effect of the BD132 Dendron AgainstPharmaceutics · 2026Article
- Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease.BMC pulmonary medicine · 2025Article
- An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Antimicrobial agents and chemotherapy · 2025Article
- Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.Scientific reports · 2023Article
- Eradication ofJournal of fungi (Basel, Switzerland) · 2021Article
- Effect of the Combination of Levofloxacin with Cationic Carbosilane Dendron and Peptide in the Prevention and Treatment ofPolymers · 2021Article
- Review
- In Vitro Evaluation of the Combination ofPathogens (Basel, Switzerland) · 2021Article
- First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.Scientific reports · 2021Article
- Feline mycobacterial disease in northern California: Epidemiology, clinical features, and antimicrobial susceptibility.Journal of veterinary internal medicine · 2021Article
- In Vitro Activity of Carbosilane Cationic Dendritic Molecules on Prevention and Treatment ofPharmaceutics · 2020Article
- Article
- Repurposing Ellipticine Hydrochloride to Combat Colistin-Resistant Extraintestinal PathogenicFrontiers in microbiology · 2020Article
- Sitafloxacin-Containing Regimen for the Treatment of RefractoryOpen forum infectious diseases · 2019Article
- Prevalence of nontuberculous mycobacteria and high efficacy of d-cycloserine and its synergistic effect with clarithromycin againstInfection and drug resistance · 2018Article
- Effects of Fluoroquinolones and Azithromycin on Biofilm Formation of Stenotrophomonas maltophilia.Scientific reports · 2016Article
- Article
- Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.Antimicrobial agents and chemotherapy · 2015Article
- Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease.Journal of pharmaceutical health care and sciences · 2015Article
- Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recommended treatments for Mycobacterium avium complex (MAC) infectious disease are combination regimens of clarithromycin (CLR) or azithromycin with ethambutol and rifamycin. However, these chemotherapy regimens are sometimes unsuccessful. Recently developed antimicrobial agents, such as newer fluoroquinolones (FQs) containing C-8 methoxy quinolone (moxifloxacin [MXF] and gatifloxacin [GAT]), are expected to be novel antimycobacterial agents. Here, we evaluated the in vitro and in vivo antimycobacterial activities of three FQs (MXF, GAT, and levofloxacin) and CLR against clinically isolated MAC strains. Subsequently, the in vitro and in vivo synergic activities of FQ-CLR combinations against MAC strains were investigated. CLR and the individual FQs alone showed promising activity against MAC strains in vitro, and the bacterial counts in organs (lungs, liver, and spleen) of MAC-infected mice treated with single agents were significantly reduced compared to control mice. CLR showed the best anti-MAC effect in vivo. When the three FQs were individually combined with CLR in vitro, mild antagonism was observed for 53 to 57% of the tested isolates. Moreover, mice were infected with MAC strains showing mild antagonism for FQ-CLR combinations in vitro, and the anti-MAC effects of the FQ-CLR combinations were evaluated by counting the viable bacteria in their organs and by histopathological examination after 28 days of treatment. Several FQ-CLR combinations exhibited bacterial counts in organs significantly higher than those in mice treated with CLR alone. Our results indicate that the activity of CLR is occasionally attenuated by combination with an FQ both in vitro and in vivo and that this effect seems to be MAC strain dependent. Careful combination chemotherapy using these agents against MAC infectious disease may be required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.